Investigating a protein's role in reducing lung inflammation in asthma
Official title: Transmembrane Protein 178 as a Novel Endogenous Inhibitory Mechanism in Asthma
Funded at Mayo Clinic Rochester · NIH-11164839 · Data updated 2026-11-12
This study is looking at a protein called Tmem178 to see how it helps reduce lung inflammation in people with asthma, and it aims to find new ways to treat asthma by understanding how this protein works in the lungs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 15, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $671,043 |
| NIH project number | 5R01HL174505-02 |
| Project ID | NIH-11164839 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with asthma, particularly those experiencing severe symptoms.
✕Less likely to help
Patients with mild asthma or those who do not have asthma may not benefit from this research.
What this research studies
This research focuses on understanding how a specific protein, Transmembrane Protein 178 (Tmem178), helps to inhibit lung inflammation associated with asthma. The study will explore how Tmem178 functions in bronchial epithelial cells and how its expression changes with asthma severity. Researchers will use a combination of cell cultures, mouse models, and genetic analysis to investigate the mechanisms by which Tmem178 regulates inflammation and airway responsiveness. By identifying the role of this protein, the research aims to uncover new therapeutic targets for asthma management.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better control asthma symptoms and reduce inflammation in patients.
How similar studies have gone: Previous research has shown promising results in targeting similar mechanisms for asthma treatment, indicating potential for success in this approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Chiarella, Sergio E — Mayo Clinic Rochester
- Study coordinator: Chiarella, Sergio E
Related research
Other NIH-funded projects on the same topics.
-
GLP-1 receptor agonists as immune targets to treat asthma in lean and obese adults
Aims to understand how GLP-1R‑agonist diabetes medicines may directly calm immune cells to reduce asthma in adults who are lean or obese.
-
Understanding how a type of immune cell called ILC2s affect asthma in adults
This grant studies how group 2 innate lymphoid cells influence asthma in adults to help identify new ways to manage airway inflammation.
-
Expanding understanding of asthma in kids through airways and blood profiling
A study at UC San Francisco will profile blood and nasal/sputum samples from 300 youth (including 200 with asthma) over a year to understand how environmental and social factors influence asthma in marginalized communities.
-
Preventing and improving asthma care for children in urban communities
This program will try several approaches — from giving helpful bacteria to babies to allergy immunotherapy and advanced airway testing — to prevent and better treat asthma in children who live in cities.
-
IDEAL project helps predict vaccine response, infections, and asthma in early childhood
A Child-focused program will collect and share saliva, blood, and tissue samples from diverse infants to find biological patterns that predict how vaccines work, how respiratory infections occur, and who develops asthma.
-
Understanding how early-life immune development affects vaccine responses and asthma risk in children
This project uses lab-grown human immune cells from infants and young children to explore why some kids respond poorly to vaccines and are more prone to respiratory infections and asthma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.